Significance of interleukin-6 (IL-6) and C-reactive protein (CRP) in children and young adults with febrile neutropenia during chemotherapy for cancer: A prospective study

Journal of Pediatric Hematology/Oncology

Volumn 34, Issue 8, 2012, Pages 617-623

  Chaudhary, Narendra ^a   Kosaraju, Kranthi ^a   Bhat, Kamalakshi ^b   Bairy, Indira ^a   Borker, Anupama ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

^b KASTURBA MEDICAL COLLEGE   (India)

Author keywords

C reactive protein; cancer; chemotherapy; febrile neutropenia; interleukin 6

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; INTERLEUKIN 6;

ABSOLUTE MONOCYTE COUNT; ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CELL COUNT; CHILD; CLINICALLY DOCUMENTED INFECTION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICALLY DOCUMENTED INFECTION; NEUTROPHIL COUNT; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PYREXIA IDIOPATHICA; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEVER; FEVER OF UNKNOWN ORIGIN; HUMANS; IMMUNOCOMPROMISED HOST; INTERLEUKIN-6; MYCOSES; NEOPLASMS; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; UNNECESSARY PROCEDURES;

EID: 84868646556     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182677fc6     Document Type: Article

References (36)

1. Koh AY, Pizzo PA. Infectious complications in pediatric cancer patients. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2011:1190-1242.
2. Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135:715-719.
3. Pizzo PA, Robichaud KJ,Wesley R, et al. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine (Baltimore). 1982;61:153-165.
4. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
5. Nijhuis CO, Kamps WA, Daenen SM, et al. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol. 2005;23:7437-7444.
6. Hartel C, Deuster M, Lehrnbecher T, et al. Current approaches for risk stratification of infectious complications in pediatric oncology. Pediatr Blood Cancer. 2007;49:767-773.
7. Santolaya ME, Alvarez AM, Aviles CL, et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clin Infect Dis. 2002;35:678-683.
8. Ammann RA, Bodmer N, Hirt A, et al. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: The prospective multicenter SPOG 2003 FN study. J Clin Oncol. 2010;28:2008-2014.
9. Ammann RA, Hirt A, Luthy AR, et al. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol. 2003;41:436-443.
10. Moon JM, Chun BJ. Predicting the complicated neutropenic fever in the emergency department. Emerg Med J. 2009;26: 802-806.
11. Santolaya ME, Alvarez AM, Avilé s CL, et al. Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenic episode. Pediatr Infect Dis J. 2007;26:794-798.
12. Avabratha KS, Rau ATK, Venkataravanamma P, et al. Significance of C-reactive protein during febrile neutropenia in pediatric malignancies. Indian Pediatr. 2009;46:797-799.
13. Santolaya ME, Cofre J, Beresi V. C-reactive protein: A valuable aid for the management of febrile children with cancer and neutropenia. Clin Infect Dis. 1994;18:589-589.
14. Katz JA, Mustafa MM, Bash RO, et al. Value of creactive protein determination in the initial diagnostic evaluation of the febrile, neutropenic child with cancer. Pediatr Infect Dis J. 1992;11:708-712.
15. Heney D, Lewis IJ, Evans SW, et al. Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia. J Infect Dis. 1992;165:886-890.
16. Diepold M, Noellke P, Duffner U, et al. Performance of interleukin-6 and interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk. BMC Infect Dis. 2008;8:28.
17. Bruserud O, Akselen PE, Berghein J, et al. Serum concentrations of E-selectin, P-selectin, ICAM-1 and interleukin 6 in acute leukaemia patients with chemotherapy-induced leucopenia and bacterial infections. Br J Haematol. 1995;91: 394-402.
18. Lehrnbecher T, Venzon D, de Haas M, et al. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis. 1999;29:414-419.
19. deBont ES, Vellenga E, Swaanenburg JC, et al. Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Brit J Haematol. 1999;107:375-380.
20. Stryjewski GR, Nylen ES, Bell MJ, et al. Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediatr Crit Care Med. 2005;6: 129-135.
21. Kitanovski L, Jazbec J, Hojker S, et al. Diagnostic accuracy of procalcitonin and interleukin-6 values for predicting bacteremia and clinical sepsis in febrile neutropenic children with cancer. Eur J Clin Microbiol Infect Dis. 2006;25:413-415.
22. Fleischhack G, Kambeck I, Cipic D, et al. Procalcitonin in paediatric cancer patients: Its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor-II. Br J Haematol. 2000;111:1093-1102.
23. Sakr Y, Sponholz C, Tuche F, et al. The role of procalcitonin in febrile neutropenic patients: Review of the literature. Infection. 2008;36:396-407.
24. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340: 448-454.
25. Abrahamsson J, Phhlman M, Mellander L. Interleukin 6, but not tumour necrosis factor-a, is a good predictor of severe infection in febrile neutropenic and non-neutropenic children with malignancy. Acta Paediatr. 1997;86:1059-1064.
26. Bruserud O, Halstensen A, Peen E, et al. Serum levels of adhesion molecules and cytokines in patients with acute leukaemia. Leuk Lymphoma. 1996;23:423-430.
27. Antonelli M, Raponi GM, Martino P, et al. High IL-6 serum levels are associated with septic shock and mortality in septic patients with severe leukopenia due to hematological ma1ignancies. Scand J Infect Dis. 1995;27:381-384.
28. Hack CE, De Groot ER, Felt-Bersma RJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood. 1989;74: 1704-1710.
29. Prat C, Sancho JM, Dominguez J. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma. 2008;49:1752-1761.
30. Buyukberber N, Buyukberber S, Sevinc A. Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients. Med Oncol. 2009;26:55-61.
31. Griffin TC, Buchanan GR. Hematologic predictors of bone marrow recovery in neutropenic patients hospitalized for fever: Implications for discontinuation of antibiotics and early discharge from the hospital. J Pediatr. 1992;121:28-33.
32. Baorto EP, Aquino VM, Mullen CA, et al. Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia. Cancer. 2001;92: 909-913.
33. Rackoff WR, Gonin R, Robinson C, et al. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol. 1996;14:919-924.
34. Klaassen RJ, Goodman TR, Pham B, et al. "Low-risk"prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol. 2000;18:1012-1019.
35. Badiei Z, Khalesi M, Alami MH, et al. Risk factors associated with life-threatening infections in children with febrile neutropenia: A data mining approach. J Pediatr Hematol Oncol. 2011;33:e9-e12.
36. Miedema KG, de Bont ES, Oude Nijhuis CS, et al. Validation of a new risk assessment model for predicting adverse events in children with fever and chemotherapy-induced neutropenia. J Clin Oncol. 2011;29:e182-e184.